Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 27, Issue 12, 2015, Pages 1747-1754

  Dlugosz, Aldona ^a   Nowak, P ^a   D'Amato, M ^a   Mohammadian Kermani, G ^a   Nystrom J ^a   Abdurahman, S ^b   Lindberg, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Flagellin; Irritable bowel syndrome; Lipopolysaccharide; Soluble CD14; Toll like receptors

Indexed keywords

CD14 ANTIGEN; FLAGELLIN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; SOLUBLE CD14 ANTIGEN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; TOLL LIKE RECEPTOR;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANXIETY; ARTICLE; BACTERIAL TRANSLOCATION; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; IMMUNOREACTIVITY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; GENETICS; IMMUNOLOGY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIGENS, CD14; DIARRHEA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLAGELLIN; GENOTYPE; HUMANS; IRRITABLE BOWEL SYNDROME; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 84947868732     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12670     Document Type: Article

References (44)

1. Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci U S A 2003; 100: 10452-9.
2. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
3. Camilleri M, Madsen K, Spiller R. Greenwood-Van Meerveld B, Verne GN. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012; 24: 503-12.
4. Gecse K, Roka R, Sera T, Rosztoczy A, Annahazi A, Izbeki F, Nagy F, Molnar T et al. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion 2012; 85: 40-6.
5. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113: 1296-306.
6. Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015; 12: 36-49.
7. Porras M, Martin MT, Yang PC, Jury J, Perdue MH, Vergara P. Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. Inflamm Bowel Dis 2006; 12: 843-52.
8. Yue C, Wang W, Tian WL, Huang Q, Zhao RS, Zhao YZ, Li QR, Li JS. Lipopolysaccharide-induced failure of the gut barrier is site-specific and inhibitable by growth hormone. Inflamm Res 2013; 62: 407-15.
9. Kuna AT. Serological markers of inflammatory bowel disease. Biochem Med (Zagreb) 2013; 23: 28-42.
10. Barbara G, Cremon C, Stanghellini V. Inflammatory bowel disease and irritable bowel syndrome: similarities and differences. Curr Opin Gastroenterol 2014; 30: 352-8.
11. Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2014; 63: 744-52.
12. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 1474-82.
13. Jonefjall B, Strid H, Ohman L, Svedlund J, Bergstedt A, Simren M. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil 2013; 25: 756-e578.
14. Martinez C, Lobo B, Pigrau M, Ramos L, Gonzalez-Castro AM, Alonso C, Guilarte M, Guila M et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013; 62: 1160-8.
15. Troseid M, Nowak P, Nystrom J, Lindkvist A, Abdurahman S, Sonnerborg A. Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. AIDS 2010; 24: 1733-7.
16. Hurley JC, Nowak P, Ohrmalm L, Gogos C, Armaganidis A, Giamarellos-Bourboulis EJ. Endotoxemia as a diagnostic tool for patients with suspected bacteremia caused by gram-negative organisms: a meta-analysis of 4 decades of studies. J Clin Microbiol 2015; 53: 1183-91.
17. Sitaraman SV, Klapproth JM, Moore DA 3rd, Landers C, Targan S, Williams IR, Gewirtz AT. Elevated flagellin-specific immunoglobulins in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2005; 288: G403-6.
18. Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res 2000; 6: 205-14.
19. Olbe L. Concept of Crohn's disease being conditioned by four main components, and irritable bowel syndrome being an incomplete Crohn's disease. Scand J Gastroenterol 2008; 43: 234-41.
20. Maes M, Twisk FN, Kubera M, Ringel K, Leunis JC, Geffard M. Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J Affect Disord 2012; 136: 909-17.
21. Maes M, Kubera M, Leunis JC, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012; 141: 55-62.
22. Vijay-Kumar M, Gewirtz AT. Role of flagellin in Crohn's disease: emblematic of the progress and enigmas in understanding inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 789-95.
23. Schoepfer AM, Schaffer T, Seibold-Schmid B, Muller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008; 20: 1110-8.
24. Ziegler TR, Luo M, Estivariz CF, Moore DA 3rd, Sitaraman SV, Hao L, Bazargan N, Klapproth JM et al. Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2008; 294: R402-10.
25. Lodrup Carlsen KC, Granum B. Soluble CD14: role in atopic disease and recurrent infections, including otitis media. Curr Allergy Asthma Rep 2007; 7: 436-43.
26. Pastor Rojo O, Lopez San Roman A, Albeniz Arbizu E, de la Hera Martinez A, Ripoll Sevillano E, Albillos Martinez A. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 269-77.
27. Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmas P, Palyu E, Udvardy M, Molnar T et al. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2011; 17: 767-77.
28. Zdolsek HA, Jenmalm MC. Reduced levels of soluble CD14 in atopic children. Clin Exp Allergy 2004; 34: 532-9.
29. Pasternak BA, D'Mello S, Jurickova II, Han X, Willson T, Flick L, Petiniot L, Uozumi N et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis 2010; 16: 856-69.
30. Funderburg NT, Stubblefield Park SR, Sung HC, Hardy G, Clagett B, Ignatz-Hoover J, Harding CV, Fu P et al. Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 2013; 140: 87-97.
31. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11: 225-9.
32. Hiki N, Berger D, Dentener MA, Mimura Y, Buurman WA, Prigl C, Seidelmann M, Tsuji E et al. Changes in endotoxin-binding proteins during major elective surgery: important role for soluble CD14 in regulation of biological activity of systemic endotoxin. Clin Diagn Lab Immunol 1999; 6: 844-50.
33. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, Downie-Doyle S, Smith E et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
34. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, Shavit Y, Ovadia H et al. Illness, cytokines, and depression. Ann N Y Acad Sci 2000; 917: 478-87.
35. Henckaerts L, Pierik M, Joossens M, Ferrante M, Rutgeerts P, Vermeire S. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007; 56: 1536-42.
36. Pierik M, Joossens S, Van Steen K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, Vermeire S. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006; 12: 1-8.
37. Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, Ferguson LR. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 2007; 102: 2504-12.
38. Kim EJ, Chung WC, Lee KM, Paik CN, Jung SH, Lee BI, Chae HS, Choi KY. Association between toll-like receptors/CD14 gene polymorphisms and inflammatory bowel disease in Korean population. J Korean Med Sci 2012; 27: 72-7.
39. Meena NK, Verma R, Verma N, Ahuja V, Paul J. TLR4 D299G polymorphism modulates cytokine expression in ulcerative colitis. J Clin Gastroenterol 2013; 47: 773-780.
40. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS ONE 2012; 7: e42777.
41. Merx S, Neumaier M, Wagner H, Kirschning CJ, Ahmad-Nejad P. Characterization and investigation of single nucleotide polymorphisms and a novel TLR2 mutation in the human TLR2 gene. Hum Mol Genet 2007; 16: 1225-32.
42. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003; 170: 5165-75.
43. Dlugosz A, Winckler B, Lundin E, Zakikhany K, Sandstrom G, Ye W, Engstrand L, Lindberg G. No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. Sci Rep 2015; 5: 8508.
44. Dlugosz A, Nowak P, Nyström J, Abdurahman S, Lindberg G. High plasma level of lipopolisaccharyde and anti-flagellin antibodies among patients with irritable bowel syndrome - signs of bacterial translocation? Gut Microbiota for Health 2nd World Summit, Madrid, 24-26 February 2013.